Ssenyonyi Tasks Government to Explain Investment in Dei-Biopharma

Leader of the Opposition in Parliament, Joel Ssenyonyi, has called on the government to explain the status of its investment in Dei-Biopharma Limited. The company was recently auctioned off due to accumulated debts amounting to 147.7 billion shillings. Ssenyonyi raised concerns about the fate of public funds invested in the company, warning that taxpayers risk losing billions of shillings if the government fails to account for its investment.

Dei-Biopharma was established to manufacture medicines and vaccines targeting diseases such as cancer and COVID-19. However, questions have emerged over the company's failure to deliver on its intended pharmaceutical production objectives. The company's financial difficulties have prompted Members of Parliament to call for a comprehensive audit to establish how public funds were utilised.

The government reportedly holds a 9.4 per cent stake in Dei-Biopharma, having invested approximately 725 billion shillings. Ssenyonyi's demand for answers follows concerns about the company's financial difficulties and the potential loss of public funds. The Leader of the Opposition in Parliament emphasised the need for accountability and transparency in the management of public funds.

Legislators are seeking clarity on accountability and the individuals responsible should investigations establish any loss or misuse of public funds. The audit will aim to determine the current value of the government's investment and the circumstances surrounding the company's financial difficulties. This move is expected to shed light on the management of public funds in Dei-Biopharma.

The development has sparked concerns about the government's investment strategy and the management of public funds in the pharmaceutical sector. Dei-Biopharma's failure to deliver on its objectives has raised questions about the effectiveness of the government's investment in the company. The opposition's demand for answers reflects growing concerns about accountability and transparency in the management of public funds.

Radio Sapientia 94.4 FM reported on the issue, citing concerns about the potential loss of public funds. The report highlighted the need for a comprehensive audit to establish the facts surrounding Dei-Biopharma's financial difficulties. The station's coverage of the issue reflects growing concerns about accountability and transparency in the management of public funds.

The government's response to Ssenyonyi's demands remains unclear. However, the opposition's call for accountability and transparency is expected to prompt a thorough investigation into the management of public funds in Dei-Biopharma. The outcome of the audit will likely shed light on the circumstances surrounding the company's financial difficulties and the potential loss of public funds.

Key points

• The government invested approximately 725 billion shillings in Dei-Biopharma, holding a 9.4 per cent stake in the company.
• Dei-Biopharma was established to manufacture medicines and vaccines targeting diseases such as cancer and COVID-19.
• The company's accumulated debts amount to 147.7 billion shillings, prompting concerns about the potential loss of public funds.